The report provides in-depth details of 20+ marketed products, which are currently leading the market. It also provides the therapeutic details of the marketed product in this area, along with their historical and forecasted sales till 2022. It also covers the 15+ companies, which are active in this field with 30+ therapeutic pipeline drugs that are currently under development for the treatment of Hepatitis C including their comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Pre-clinical and Discovery stage products. Additionally, Forecasted sales of Phase III drugs are also incorporated in the report. A separate section for inactive products is also included in the report.
Comparative analysis of therapeutic drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. The report also provides the market drivers and barriers for Hepatitis C drugs for the enhanced pipeline of Hepatitis C. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Note: Please allow up to 24 hours for delivery after payment has been made.
Last Stage Products (Filed and Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Pre-clinical and Discovery Stage Products
Therapeutic Assessment: Active Products
Market Drivers and Barriers
List of Tables
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
List of Figures
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Total Products for Hepatitis C
Figure 5: Late Stage Products (Filed and Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical and Discovery Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Therapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Stage and Molecule Type
Figure 14: Dormant Products
Figure 15: Discontinued Products